Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Nuclear cap-binding protein subunit 3 (NCBP3) is a protein that forms an alternative cap-binding complex (CBC) with NCBP1/CBP80 in eukaryotic cells[5][1][2]. NCBP3 binds to RNA at the 7-methylguanosine (m^7^G) cap and serves as an adapter protein for capped RNAs, facilitating their export from the nucleus, particularly for mRNAs rather than small nuclear RNAs (snRNAs)[2][5]. This alternative CBC is essential during cellular stress (such as viral infection or cell transformation) and contributes to antiviral defense mechanisms by ensuring efficient mRNA export and possibly impacting mRNA processing steps like splicing and 3′ end formation[1][3][4][5]. NCBP3 is part of RNA metabolic networks, interacting with protein partners distinct from canonical CBC components and with complexes involved in mRNA export and processing, such as the EJC and TREX complexes[3]. It is localized to the nucleus and nuclear speckles but can also be detected in the cytoplasm[5][4].\n\n**NCBP3 is not regarded as a direct therapeutic target such as a receptor, enzyme, or transporter, and there is no current evidence of approved drugs that modulate its activity or function.**
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Nuclear cap-binding protein subunit 3 (NCBP3).